Novo Nordisk Shares Plunge Following Clinical Trial Setback and Strategic Shifts

Novo Nordisk shares hit multi-year low after CagriSema trial fails and it slashes Wegovy/Ozempic prices. Eli Lilly gains ground in weight-loss drug market.

The Danish pharmaceutical giant Novo Nordisk is navigating one of its most challenging periods in recent memory. Once a darling of the equity markets, the company now contends with a failed high-profile drug trial, significant price reductions, and a sobering financial outlook. As competitor Eli Lilly gains ground in the lucrative weight-loss drug sector, investors are assessing whether the severe share price decline represents a temporary stumble or a more fundamental threat to the business.

Stock Price Reaches Multi-Year Low

A confluence of negative developments has sent Novo Nordisk's equity value to a multi-year low. The stock currently trades at 32.03 euros, reflecting a loss exceeding 22 percent in just the past week. The broader picture is even more stark: from its 52-week high of 87.10 euros, the share price has more than halved, marking a 63 percent decline. Management's forecast for 2026 offers little hope for a swift rebound, having already projected decreases in both sales and operating profit.

Phase 3 Trial Failure Delivers Major Blow

The immediate catalyst for the sell-off was the unexpected failure of the crucial Phase 3 trial for the drug candidate CagriSema. This medication was positioned as Novo Nordisk's key weapon to recapture market share from Eli Lilly. The results, however, were broadly disappointing. While patients on the rival therapy Zepbound achieved an average weight loss of 25.5 percent, subjects on CagriSema over 84 weeks reached only 23 percent, missing the study's primary endpoint.

Analyst reactions were severe. Barclays slashed its revenue forecast for the drug dramatically from $12 billion to just $2 billion—a reduction of over 80 percent. According to media reports, an analyst from Jyske Bank described the outcome as a "colossal own goal." The failure has significantly shaken confidence in the firm's innovation pipeline, as CagriSema was a central growth driver slated for the coming years.

Strategic Pivot Amid Price Pressure

Compounding the clinical trial disappointment, the group announced drastic price cuts in the United States almost simultaneously. Effective January 1, 2027, the list prices for its blockbuster drugs Wegovy and Ozempic are set to be reduced by up to 50 percent. This move responds to mounting political pressure from the Inflation Reduction Act and intensifying competition. While intended to improve patient access, the cuts will inevitably pressure profit margins.

A strategic bright spot emerged mid-week with the announced partnership with U.S. startup Vivtex. Novo Nordisk is committing up to $2.1 billion to develop technologies for the oral administration of medications. This underscores an attempt to reduce reliance on injectable solutions and broaden its portfolio.

Critical Months Ahead for the Pharma Leader

The coming months are pivotal for Novo Nordisk. Short-term catalysts are scarce, as competitor Eli Lilly is expected to launch its own tablet in the second quarter, and the commercial prospects for CagriSema have dimmed considerably. Investor attention now turns to May 6, 2026, when the next quarterly figures must indicate whether a bottom has been reached. This precedes the capital markets day scheduled for September in London.